stockrow
Saturday 7 November 2026
Export FHTX’s income statement to Excel — free account
Foghorn Therapeutics Inc.
FHTX Healthcare Biotechnology
Foghorn Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $30.9 million, up 36.8% from fiscal 2024.
- Revenue
- +112.7%
- EPS
- +64.3%
- Free cash flow
- +14.9%
Quarter to June 2026, against a year earlier
1.87
0.04
−2.09%
Follow FHTX
Alert me
Foghorn Therapeutics Inc. (FHTX) P/E ratio
Foghorn Therapeutics Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 41.0× (December 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 20 more quarters | Free account |
Against its own ten years
Low 0.0×
High 41.0×
Ten-year median
0.0×
Current reading's percentile
96
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NKTX Nkarta, Inc. compare | n/m |
| CHRS Coherus Oncology, Inc. compare | n/m |
| FHTX Foghorn Therapeutics Inc. | n/m |
| PYPD PolyPid Ltd. compare | n/m |
| CDXS Codexis, Inc. compare | n/m |
| NERV Minerva Neurosciences, Inc compare | n/m |
| HUMA Humacyte, Inc. compare | n/m |
| ARMP Armata Pharmaceuticals, Inc. compare | n/m |
| ENGN enGene Therapeutics Inc compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)